摘要目的 总结肾移植术后因某些原因而撤除环孢素A(CsA)的经验教训,并对其可行性及安全性进行评价.方法 总结20例术后撤除CsA的肾移植患者的有关资料.结果 20例患者在撤除CsA并同时调整其它免疫抑制剂剂量后,其肾功能、肝功能及白细胞计数等与撤药前比较,差异均无显著性;与同期常规治疗者比较,两组肾功能的差异也无显著性.结论 在调整其它免疫抑制剂剂量的前提下,逐步减少CsA的用量并最终撤除CsA,可以是安全的,但并不提倡,因为使用CsA,利大于弊,若确需撤CsA,应在移植医师的指导及严密监测下进行.

abstractsObjective To assess the safety and feasibility of cyclosporine A (CsA) withdrawal for some causes after kidney transplantation. Methods The data for 20 renal allograft recipients who withdrew CsA from normal triple immunosuppressive regime under the guide of transplant experts were retrospectively analyzed. Results All patients survived with steady graft function till now. No significant difference in serum creatine, ALT levels and WBC count was found between pre-withdrawal and post-withdrawal of CsA. As compared kidney function of 10 CsA-withdrawn and survived more than 5 years' patients with the results of other 13 patients transplanted during the corresponding period, there were no significant difference also. Conclusion Under the regulation of other immunosuppressive doses, it is safety that CsA dose was gradually decreased and finally withdrawn. Meanwhile it should be emphasized that, though CsA had certain side effects,it was not recommended to withdraw CsA willfully, because the advantages of CsA therapy certainly surpassed its disadvantages.